Every diagnosis is personal—a unique molecular fingerprint telling the story of your body. Precision medicine offers hope by honoring that individuality, designing care made just for you. Yet, unlocking the full potential of your molecular fingerprint remains a challenge—one that continues to drive innovation, turning complexity into clarity and hope.

Dr. George Poste was recently named as the recipient of the 2025 Award for Leadership in Personalized Medicine by the Personalized Medicine Coalition Board of Directors for his multi-decade contributions to personalized medicine, biosecurity and global public health. He shares this distinguished award with the likes of Dr. Francis S. Collins, M.D., Ph.D., Dr. Carl H. June, M.D., Dr. Leroy Hood, Ph.D., M.D., Dr. Janet Woodcock, M.D. – all pioneers in  forging conceptual and technological advances in precision health. 

In addition to his distinguished academic and leadership career, Dr. Poste played a pivotal role in the founding of Caris Life Sciences, now one of the largest companies in precision oncology. Today, Caris operates extensive R&D facilities in Phoenix, including the largest genome sequencing capabilities in the United States—an investment that underscores the city’s growing role in advancing precision medicine.

Recently, Dr. Poste shared a sweeping overview of the field’s origins, breakthroughs, and future directions in a discussion with Scarlett Spring, Exec. Dir. of the PBC. Their conversation touched on everything from molecular biology’s early days to the revolutionary rise of AI-driven “digital twins” and the growing importance of social and environmental factors in health outcomes.

From Molecular Biology to Personalized Medicine

Dr. Poste traces the roots of precision medicine and oncology back to the early 1980s, when advances in biotechnology and molecular biology revealed that many major diseases are not single entities but rather collections of distinct molecular subtypes. In addition to heterogeneity of disease subtypes, diseases like cancer exhibit additional extravagant patterns of heterogeneity at the cellular and molecular level in different patients. This “daunting heterogeneity,” as he calls it, upends the previous one-size-fits-all approach to diagnosis and treatment.

“You’ve got to be an optimist to be in this business because it’s so complex and so many things can go wrong,” Poste reflected. This complexity, however, has also opened the door to more nuanced diagnostics and targeted therapies tailored to the specific molecular characteristics of each disease subtype.

He emphasizes that precision medicine today remains less about purely individualized treatments and more about defining groups of patients with shared molecular profiles, leading to more precise but still population-based interventions. “Precision is probably a more accurate element of where we are today because we’re talking about treating groups of people which are related,” he said.

The Power of Data: Biobanks and AI

Recognizing that  validation of molecular biomarkers to profile disease heterogeneity required research on very large numbers of patient tissue samples, he played a key role in the development of the UK Biobank in 1991—an unprecedented effort to collect biological samples and health data from 500,000 participants. This resource established a prototype on how to track the molecular changes that occur over time in the continuum from health to disease.

Today, this vision is embodied in the concept of “digital twins”: virtual models of patients created by integrating massive datasets, allowing physicians to select treatment and predict outcomes based on thousands of similar cases.

The computational horsepower of machine learning and artificial intelligence makes it possible to process two to four terabytes of molecular profiling data per patient, a feat unimaginable even five-years ago.

Liquid Biopsies: A Less Invasive Window into Cancer

One of the most promising recent advances Dr. Poste highlighted is the shift in oncology from traditional tissue biopsies to liquid biopsies. These blood-based tests provide a minimally invasive way to profile tumors molecularly, offering not only diagnosis but also enable continuous monitoring over time.

This technology enables detection of minimal residual disease (MRD)—cancer cells that linger after treatment and can signal a relapse before a recurrent tumor becomes visible. Poste poignantly noted, “The two worst things a cancer patient wants to hear are one, ‘I’m very sorry you got cancer.’ The second is ‘I’m very sorry it’s come back.’”

Liquid biopsies offer hope to catch the disease early and adapt therapies to the evolving tumor, including confronting the problem of drug resistance to improve patient outcomes.

Beyond Oncology and The Challenge of the Exposome

While cancer has been at the forefront of precision medicine, the same principles are expanding to other complex diseases including cardiovascular, metabolic, autoimmune, neuropsychiatric disorders and degenerative diseases like Alzheimer’s.

Yet, as Dr. Poste cautions, the greatest challenges ahead are not purely technological. Social determinants and environmental exposures—what he calls the “exposome”—have profound impacts on health and disease but remain poorly understood. He pointed to disparities like a 20-year difference in life expectancy between two neighborhoods in Phoenix as evidence that genes alone don’t tell the whole story.

Understanding how the exposome interacts with our genes to produce what is referred to as epigenetic alterations represents a vast, largely unexplored frontier that will require new scientific and societal approaches.

A Journey of Progress and Complexity

Reflecting on the field’s progress, Dr. Poste urged humility alongside optimism. “We should take appropriate pride in the journey taken. But at the same time, we should be under no illusion about the complexities that we still face.” The road ahead in precision medicine will require sophisticated integration of molecular biology, clinical medicine, AI and social science in unprecedented ways. This convergence will require substantial changes in the way research is organized and care delivered.

We are entering a new era—what Dr. Poste calls “beyond oncology”—where precision medicine extends to all diseases and is no longer just hope but routine reality. Yet, the biggest breakthroughs won’t come from technology alone. Understanding the exposome—the environmental and social factors shaping our health—is crucial.

This challenge calls for new thinking, collaboration, and a commitment to redress disparities in access, availability and affordability of care. The challenge is clear: the journey is complex, but the promise is profound. 

Dr. Poste’s award will be presented at the 19th Annual Personalized Medicine Conference, to be held November 13–14, 2025, at the Ritz-Carlton Laguna Niguel in Dana Point, California (https://www.personalizedmedicineconference.org/) after which he will provide a lecture on his perspectives on the future evolution of precision health.